XPH - SPDR® S&P Pharmaceuticals ETF
| Previous Close | 40.94 |
| Open | 41.08 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 40.47 - 41.33 |
| 52 Week Range | 39.78 - 47.11 |
| Volume | 48,427 |
| Avg. Volume | 77,091 |
| Net Assets | 360.22M |
| NAV | 41.88 |
| PE Ratio (TTM) | N/A |
| Yield | 0.68% |
| YTD Return | -3.70% |
| Beta (3y) | 1.14 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2006-06-19 |
- Market Realist•17 hours ago
Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.
- Market Realist•15 days ago
How Johnson & Johnson Stock Performed in 1Q18
Headquartered in New Brunswick, New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical and healthcare companies in the world.
- Market Realist•21 days ago
Johnson & Johnson’s Valuation in March 2018
Analyzing Johnson & Johnson’s Stock and Valuations in March 2018
- Barrons.com•23 days ago
Antibiotics Could Clean Up as M&A Catalyst
Antibiotics are the most commonly prescribed class of drug, and represent a $40 billion market globally. There have only been 10 new Food and Drug Administration approvals for antibiotics since 2010, and while they were developed by eight different companies, now just four--Allergan (AGN), Johnson & Johnson (JNJ), Merck (MRK), and Melinta Therapeutics (MLNT)--own them.
- Market Realist•26 days ago
How Merck’s Business Segments Performed
What Analysts Recommend for Merck in March 2018
- Market Realist•last month
These Pfizer Products Saw Declining Sales in 4Q17
An Overview of Pfizer's 4Q17: What Lies Ahead?
- ETF Trends•last month
Pharmaceutical ETF Surges on Healthy Outlook
Investors looking to play a rebound in pharmaceuticals stocks have an array of exchange traded funds to consider. The SPDR Pharmaceuticals ETF (NYSEArca: XPH) is an equal-weight approach to pharmaceuticals ...
- Market Realist•2 months ago
Comparing Eli Lilly’s Post-4Q17 Valuation
How 4Q17 Turned Out for Eli Lilly
- Market Realist•2 months ago
What’s Pfizer’s Valuation after 4Q17 Earnings?
How Did Pfizer Fare in 4Q17?
- MarketWatch•3 months ago
Pharmaceutical stocks drop after drug price mention in Trump’s State of the Union
Trump described drug prices as “one of my greatest priorities,” but his administration has released nothing in the way of policy over the last year.
- Investopedia•3 months ago
Top 5 Pharmaceutical ETFs for 2018
Details on the five top healthcare pharmaceutical ETFs for 2018.
- Market Realist•3 months ago
Eli Lilly’s 4Q17 Estimates: Elanco
A Preview of Eli Lilly’s 4Q17 Earnings Release on January 31
- Market Realist•3 months ago
Johnson & Johnson’s Pharmaceuticals Business in 4Q17
Must-Read Notes on Johnson & Johnson’s 4Q17 Earnings
- Market Realist•3 months ago
Pfizer: Revenue Growth Is Expected in 4Q17
What to Expect from Pfizer’s 4Q17 Earnings on January 30
- Market Realist•3 months ago
Merck & Co.’s Animal Health Business in 3Q17
Who’s Watching Merck & Co. in January 2018?
- Market Realist•3 months ago
Johnson & Johnson’s Revenue Estimates for 4Q17
As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.
- Investopedia•3 months ago
Supernus Pharmaceuticals Stock Is an Institutional Favorite
Accumulation by institutional investors could continue to drive the performance of Supernus Pharmaceuticals shares.
- InvestorPlace•3 months ago
Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been on a tear in recent months, nearly doubling since November 1, when it closed at $11.93 a share. Valeant announced its results on November 7, with the news it beat analyst estimates for both revenue and net income. The company has also made progress in reducing its substantial debt burden.
- Investopedia•3 months ago
Corcept Therapeutics Stock Has Healthy Institutional Support
Institutions appear bullish on Corcept shares, which could suggest a buying opportunity for long-term investors.
- Investopedia•4 months ago
Top 5 Pharmaceutical ETFs for 2018
Details on the five top healthcare pharmaceutical ETFs for 2018.
- CNBC Videos•3 months ago
Health-care ETFs in focus on JP Morgan-Berkshire-Amazon d...
CNBC's Mike Santoli takes a look at which ETFs could be affected by the announcement that J.P. Morgan, Berkshire Hathaway and Amazon are teaming up to form a health-care company.
Yahoo Finance Video•3 months agoMylan CEO: I'm excited about our pipeline
CEO of pharmaceutical company Mylan, Heather Bresch, sits down the Yahoo Finance's Andy Serwer and Jen Rogers to discuss what the future holds for the drug company.
